CAJ | 학술논문

目的：观察伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌（ NSCLC ）的近期疗效及毒副作用。方法：晚期非小细胞肺癌68例中，伊立替康联合奥沙利铂组（ A组）36例，采用伊立替康100 mg/m2，第1、8天；奥沙利铂130 mg/m2，第2天，静脉滴注。多西他赛联合奥沙利铂组（ B组）32例，采用多西他赛75 mg/m2，第1天；奥沙利铂130 mg/m2，第2天，静脉滴注。21天为1周期，连用2周期后评定疗效。结果：A组和B组有效率分别为41．67％和31．25％，两组差异无统计学意义（ P＞0．05）。 A组迟发性腹泻和胆碱性综合征发生率明显高于B组（P＜0．01），但A组粒细胞减少发生率明显低于B组（P＜0．05）。结论：伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌有较好的疗效，不良反应可以耐受，安全性好，可以考虑作为晚期非小细胞肺癌治疗方案之一。
목적：관찰이립체강혹다서타새연합오사리박치료만기비소세포폐암（ NSCLC ）적근기료효급독부작용。방법：만기비소세포폐암68례중，이립체강연합오사리박조（ A조）36례，채용이립체강100 mg/m2，제1、8천；오사리박130 mg/m2，제2천，정맥적주。다서타새연합오사리박조（ B조）32례，채용다서타새75 mg/m2，제1천；오사리박130 mg/m2，제2천，정맥적주。21천위1주기，련용2주기후평정료효。결과：A조화B조유효솔분별위41．67％화31．25％，량조차이무통계학의의（ P＞0．05）。 A조지발성복사화담감성종합정발생솔명현고우B조（P＜0．01），단A조립세포감소발생솔명현저우B조（P＜0．05）。결론：이립체강혹다서타새연합오사리박치료만기비소세포폐암유교호적료효，불량반응가이내수，안전성호，가이고필작위만기비소세포폐암치료방안지일。
Objective:To observe and compare the recent objective response rate and adverse reaction of irinotecan or docetaxe combined with oxaliplatin in the treatment of advanced non -small cell lung cancer (NSCLC).Methods:68 patients with advanced NSCLC were divided into group A consisted of 36 patients re-ceived irinotecan plus oxaliplatin and group B consisted of 32 patients received docetaxe plus oxaliplatin with a 21-day regimen.Group A:irinotecan 100 mg/m2 ,day 1,8;oxaliplatin 130 mg/m2 ,day 2.Group B:docetaxe 75 mg/m2 ,day 1;oxaliplatin 130 mg/m2 ,day 2.Two or more cycles of chemotherapy were completed in each group.Results:68 patients were assessable for efficacy and toxicities .The effective rate in group A was 41.67%and in group B was 31.25%.The effective rate between the two groups had no significant difference ( P >0.05).Group A had higher frequencies of delay diarrhoea and cholinergic syndrome (P<0.01).The incidence of myelosuppression in group A was significantly lower than the group B (P<0.05).Conclusions:Irinotecan combined with oxaliplatin is active in the treatment of advanced NSCLC ,and the adverse reactions can be tolera-ted.It is a salvage regimen for advanced NSCLC .